Studies of SARS virus vaccines.
Identifieur interne : 001D28 ( Ncbi/Curation ); précédent : 001D27; suivant : 001D29Studies of SARS virus vaccines.
Auteurs : B J Zheng [Hong Kong] ; L Y Du ; G Y Zhao ; Y P Lin ; H Y Sui ; C. Chan ; S. Ma ; Y. Guan ; K Y YuenSource :
- Hong Kong medical journal = Xianggang yi xue za zhi [ 1024-2708 ] ; 2008.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Animaux, Contrôle des maladies contagieuses, Femelle, Flambées de maladies (), Hong Kong, Humains, Injections musculaires, Modèles animaux de maladie humaine, Mâle, Prévision, Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (épidémiologie), Vaccination (), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins antiviraux (pharmacologie), Vaccins inactivés (administration et posologie), Valeur prédictive des tests, Virus du SRAS (immunologie), Évaluation des risques.
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins inactivés.
- immunologie : Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- pharmacologie : Vaccins antiviraux.
- épidémiologie : Syndrome respiratoire aigu sévère.
- Administration par voie nasale, Animaux, Contrôle des maladies contagieuses, Femelle, Flambées de maladies, Hong Kong, Humains, Injections musculaires, Modèles animaux de maladie humaine, Mâle, Prévision, Souris, Syndrome respiratoire aigu sévère, Vaccination, Valeur prédictive des tests, Évaluation des risques.
- Wicri :
- geographic : Hong Kong.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Communicable Disease Control, Disease Models, Animal, Disease Outbreaks (prevention & control), Female, Forecasting, Hong Kong, Humans, Injections, Intramuscular, Male, Mice, Predictive Value of Tests, Risk Assessment, SARS Virus (immunology), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Vaccination (statistics & numerical data), Vaccines, Inactivated (administration & dosage), Viral Vaccines (administration & dosage), Viral Vaccines (immunology), Viral Vaccines (pharmacology).
- MESH :
- chemical , administration & dosage : Vaccines, Inactivated, Viral Vaccines.
- chemical , immunology : Viral Vaccines.
- chemical , pharmacology : Viral Vaccines.
- geographic : Hong Kong.
- epidemiology : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Disease Outbreaks, Severe Acute Respiratory Syndrome.
- statistics & numerical data : Vaccination.
- Administration, Intranasal, Animals, Communicable Disease Control, Disease Models, Animal, Female, Forecasting, Humans, Injections, Intramuscular, Male, Mice, Predictive Value of Tests, Risk Assessment.
Abstract
1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.
PubMed: 18708674
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001998
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001998
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001A01
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001D28
Links to Exploration step
pubmed:18708674Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Studies of SARS virus vaccines.</title><author><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Microbiology, The University of Hong Kong, Pokfulam</wicri:regionArea><wicri:noRegion>Pokfulam</wicri:noRegion></affiliation></author><author><name sortKey="Du, L Y" sort="Du, L Y" uniqKey="Du L" first="L Y" last="Du">L Y Du</name></author><author><name sortKey="Zhao, G Y" sort="Zhao, G Y" uniqKey="Zhao G" first="G Y" last="Zhao">G Y Zhao</name></author><author><name sortKey="Lin, Y P" sort="Lin, Y P" uniqKey="Lin Y" first="Y P" last="Lin">Y P Lin</name></author><author><name sortKey="Sui, H Y" sort="Sui, H Y" uniqKey="Sui H" first="H Y" last="Sui">H Y Sui</name></author><author><name sortKey="Chan, C" sort="Chan, C" uniqKey="Chan C" first="C" last="Chan">C. Chan</name></author><author><name sortKey="Ma, S" sort="Ma, S" uniqKey="Ma S" first="S" last="Ma">S. Ma</name></author><author><name sortKey="Guan, Y" sort="Guan, Y" uniqKey="Guan Y" first="Y" last="Guan">Y. Guan</name></author><author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K Y" last="Yuen">K Y Yuen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18708674</idno><idno type="pmid">18708674</idno><idno type="wicri:Area/PubMed/Corpus">001998</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001998</idno><idno type="wicri:Area/PubMed/Curation">001998</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001998</idno><idno type="wicri:Area/PubMed/Checkpoint">001A01</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A01</idno><idno type="wicri:Area/Ncbi/Merge">001D28</idno><idno type="wicri:Area/Ncbi/Curation">001D28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Studies of SARS virus vaccines.</title><author><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Microbiology, The University of Hong Kong, Pokfulam</wicri:regionArea><wicri:noRegion>Pokfulam</wicri:noRegion></affiliation></author><author><name sortKey="Du, L Y" sort="Du, L Y" uniqKey="Du L" first="L Y" last="Du">L Y Du</name></author><author><name sortKey="Zhao, G Y" sort="Zhao, G Y" uniqKey="Zhao G" first="G Y" last="Zhao">G Y Zhao</name></author><author><name sortKey="Lin, Y P" sort="Lin, Y P" uniqKey="Lin Y" first="Y P" last="Lin">Y P Lin</name></author><author><name sortKey="Sui, H Y" sort="Sui, H Y" uniqKey="Sui H" first="H Y" last="Sui">H Y Sui</name></author><author><name sortKey="Chan, C" sort="Chan, C" uniqKey="Chan C" first="C" last="Chan">C. Chan</name></author><author><name sortKey="Ma, S" sort="Ma, S" uniqKey="Ma S" first="S" last="Ma">S. Ma</name></author><author><name sortKey="Guan, Y" sort="Guan, Y" uniqKey="Guan Y" first="Y" last="Guan">Y. Guan</name></author><author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K Y" last="Yuen">K Y Yuen</name></author></analytic><series><title level="j">Hong Kong medical journal = Xianggang yi xue za zhi</title><idno type="ISSN">1024-2708</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Communicable Disease Control</term><term>Disease Models, Animal</term><term>Disease Outbreaks (prevention & control)</term><term>Female</term><term>Forecasting</term><term>Hong Kong</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Mice</term><term>Predictive Value of Tests</term><term>Risk Assessment</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Vaccination (statistics & numerical data)</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Contrôle des maladies contagieuses</term><term>Femelle</term><term>Flambées de maladies ()</term><term>Hong Kong</term><term>Humains</term><term>Injections musculaires</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Prévision</term><term>Souris</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Vaccination ()</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (pharmacologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Valeur prédictive des tests</term><term>Virus du SRAS (immunologie)</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Hong Kong</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Communicable Disease Control</term><term>Disease Models, Animal</term><term>Female</term><term>Forecasting</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Mice</term><term>Predictive Value of Tests</term><term>Risk Assessment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Contrôle des maladies contagieuses</term><term>Femelle</term><term>Flambées de maladies</term><term>Hong Kong</term><term>Humains</term><term>Injections musculaires</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Prévision</term><term>Souris</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccination</term><term>Valeur prédictive des tests</term><term>Évaluation des risques</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Hong Kong</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001D28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:18708674
|texte= Studies of SARS virus vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:18708674" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |